

The ACRO Resident Committee has assembled the following resource sheet for residents and practicing radiation oncologists. This is not intended to be a study guide as there are numerous iterations available online and for purchase. Rather, this is intended to be a practical reference, with emphases on contouring, guidelines, *accessible* protocols, and toxicity information that may help radiation oncologists with treatment and patient discussions. This is by no means an exhaustive list, and we welcome suggestions for additional resources/edits. We hope this resource benefits your training and practice.

~ACRO Resident Education Subcommittee

1. The Basics

- a. National Comprehensive Cancer Network (NCCN): <https://www.nccn.org/>
- b. NCCN Radiation Therapy Compendium: <https://www.nccn.org/professionals/radiation/Default.aspx>
- c. Choosing Wisely ASTRO: <http://www.choosingwisely.org/societies/american-society-for-radiation-oncology/>
- d. RCR Doses and Fractionation: <https://www.rcr.ac.uk/publication/radiotherapy-dose-fractionation-third-edition>
- e. ACR Appropriateness Criteria: <https://www.acr.org/Clinical-Resources/ACR-Appropriateness-Criteria>

2. Staying Up To Date Resources

- a. QuadShot: <http://www.quadshotnews.com/>
- b. ACR Journal Advisor: <https://www.acrjournaladvisor.com/>
- c. The Mednet: <https://www.themednet.org/>
- d. ACRO YouTube Channel: <https://www.youtube.com/channel/UCSzpY2tx6ujMHFghiC65a8g>

3. Education Resources

- a. Radiation Oncology Education Collaborative Study group (ROECSG) web resources: <https://voices.uchicago.edu/roecsg/web-resources/study-materials/>
- b. Estes RadOnc Tables Guides: <https://radonctables.wordpress.com/2017/08/31/first-blog-post/>
- c. RadOncQuestions.com Question Bank: <https://www.radoncquestions.com/>
- d. Association of Residents in Radiation Oncology (ARRO) Resident Resources: <https://www.astro.org/Affiliate/ARRO/Resident-Resources>
- e. Rad Onc Review: <https://www.radoncreview.org/>

4. General Contouring and Planning Resources

- a. eContour: <https://econtour.org/>
- b. Standardizing Normal Tissue Contouring ASTRO Consensus (Table E1 & E2): <https://www.ncbi.nlm.nih.gov/pubmed/30576843>
- c. AAPM TG 101 - SBRT constraints: <https://www.aapm.org/pubs/reports/detail.asp?docid=102>
- d. UK Consensus on normal tissue constraints for SBRT: <https://pubmed.ncbi.nlm.nih.gov/29033164/>
- e. How Path and Recurrence Patterns Inform CTV: <https://www.ncbi.nlm.nih.gov/pubmed/29933882>
- f. CB-CHOP plan evaluation system: <https://appliedradiationoncology.com/articles/cb-chop-a-simple-acronym-for-evaluating-a-radiation-treatment-plan>
- g. Meet me in Treatment Planning: <https://www.astro.org/Affiliate/ARRO/Resident-Resources/Educational-Resources/ASTRO-ARRO-Meet-Me-in-Treatment-Planning-Webinars>
- h. Chartounds.com: <https://chartounds.com/>

5. Students Resources

- a. Radiation Oncology: a Primer for Medical Students: <https://www.ncbi.nlm.nih.gov/pubmed/23807599>
- b. ROECSG Intro to Radiation Oncology: <https://voices.uchicago.edu/roecsg/introduction-to-radiation-oncology/>
- c. Applying to Radiation Oncology: <https://www.youtube.com/watch?v=faLDYAqABxg>

6. Patient Education Resources

- a. ASTRO Videos: <https://www.astro.org/Patient-Care-and-Research/Patient-Education/Patient-Videos>
- b. ASTRO Brochures: <https://www.astro.org/Patient-Care-and-Research/Patient-Education/Patient-Brochures>
- c. ACS: <https://www.cancer.org/health-care-professionals/patient-education-materials-for-professionals.html>
- d. NCI: <https://www.cancer.gov/publications/patient-education>
- e. ASCO: <https://www.cancer.net/about-us/asco-answers-patient-education-materials/asco-answers-fact-sheets>
- f. ESMO: <https://www.esmo.org/for-patients>
- g. JAMA, What is SBRT? <https://jamanetwork.com/journals/jamaoncology/fullarticle/2720476>

7. Prostate (Fossa)

- a. Contouring
 - i. RTOG consensus guidelines: <https://www.ncbi.nlm.nih.gov/pubmed/19394158>
 - ii. RTOG atlas: <https://www.rtog.org/CoreLab/ContouringAtlases/ProstatePostOp.aspx>
 - iii. eContour training module (Prostate Fossa): https://econtour.org/training/prostate_fossa_module.pdf
 - iv. RTOG normal tissue contouring guidelines: <https://www.ncbi.nlm.nih.gov/pubmed/22483697>
- b. Society Guidelines
 - i. ASTRO: <https://www.astro.org/Patient-Care-and-Research/Clinical-Practice-Statements/ASTRO-39;s-guideline-on-adjuvant-and-salvage-RT-af>
- c. Relevant Accessible Radiation Protocols
 - i. RTOG 0543 (SPPORT). Salvage with/without pelvis with/without ADT: <https://www.rtog.org/clinicaltrials/protocoltable/studydetails.aspx?action=openFile&FileID=13044>
- d. Quality of Life/Toxicity
 - i. SWOG 8794 RP and obs vs adj RT: <https://www.ncbi.nlm.nih.gov/pubmed/18165645>
 - ii. SAKK 09/10 standard vs high dose salvage RT: <https://www.ncbi.nlm.nih.gov/pubmed/26527774>
 - iii. German analysis RP only vs adj RT vs adj ADT vs adj RT + ADT: <https://www.ncbi.nlm.nih.gov/pubmed/27887941>
 - iv. Patient reported outcomes after postprostatectomy IMRT: <https://pubmed.ncbi.nlm.nih.gov/31113644/>

8. Prostate (Intact)

- a. Contouring
 - i. Combined RMH and RTOG guidelines: <https://www.ncbi.nlm.nih.gov/pubmed/26104940>
 - ii. RTOG atlas: <https://www.rtog.org/CoreLab/ContouringAtlases/ProstatePelvicLymphNodes.aspx>
 - iii. eContour training module (Intact Prostate): https://econtour.org/training/intact_prostate_module.pdf
 - iv. RTOG normal tissue contouring guidelines: <https://www.ncbi.nlm.nih.gov/pubmed/22483697>
- b. Society Guidelines
 - i. ASTRO: <https://www.astro.org/Patient-Care-and-Research/Clinical-Practice-Statements/ASTRO-39;s-evidence-based-guideline-on-clinically>
 - ii. ASTRO/ASCO/AUA hypo-fractionation: <https://www.ncbi.nlm.nih.gov/pubmed/30307776>
 - iii. ABS: <https://www.americanbrachytherapy.org/consensus-statements/prostate/>
 - iv. GEC/ESTRO HDR: <https://www.ncbi.nlm.nih.gov/pubmed/23773409>
- c. Relevant Accessible Radiation Protocols
 - i. Standard fractionation

1. RTOG 0815. Dose escalation with/without ST-ADT in intermediate prostate: <https://www.rtog.org/clinicaltrials/protocoltable/studydetails.aspx?action=openFile&FileID=13149>
2. RTOG 0924. Dose escalation and ADT with/without whole pelvis in unfavorable risk: <http://rpc.mdanderson.org/rpc/credentialing/files/0924.pdf>
- ii. Hypo-fractionation
 1. CHHiP constraints (Supplementary>Table 2): <https://www.ncbi.nlm.nih.gov/pubmed/27339115>
 2. PROFIT (Supplementary>protocol): <https://www.ncbi.nlm.nih.gov/pubmed/28296582>
 3. RTOG 0415 (Supplementary>protocol): <https://www.ncbi.nlm.nih.gov/pubmed/27044935>
 4. HYPO-RT-PC: <https://www.umu.se/globalassets/centralwebb/forskningswebb/forskningsamnen/cancer/protocol-hypo-trial-v.-7-non-inf-scand--2015-10-15-final.pdf>
- iii. Stereotactic body radiotherapy (SBRT)
 1. RTOG 0938. 5fx vs 12fx SBRT: <https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=8416>
- iv. Combined external beam and brachytherapy
 1. ASCENDE-RT (Supplementary Material): <https://pubmed.ncbi.nlm.nih.gov/28262473/>
- d. Quality of Life/Toxicity
 - i. ProtecT QoL AS vs RP vs RT: <https://www.ncbi.nlm.nih.gov/pubmed/27626365>
 - ii. PROST-QA trial: <https://www.ncbi.nlm.nih.gov/pubmed/18354103/>
 - iii. DART 01/05 short vs long term ADT: <https://www.ncbi.nlm.nih.gov/pubmed/27598804>
 - iv. RTOG 0938 SBRT PRO: <https://www.ncbi.nlm.nih.gov/pubmed/29913254>
 - v. ASCENDE-RT tox analysis: <https://www.ncbi.nlm.nih.gov/pubmed/28433432>

9. NSCLC (Early)

- a. Contouring
 - i. eContour OAR module: <https://econtour.org/cases/89>
 - ii. EORTC contouring and treatment planning guidelines: <https://pubmed.ncbi.nlm.nih.gov/28666551/>
- b. Society Guidelines
 - i. ASTRO: <https://www.astro.org/Patient-Care-and-Research/Clinical-Practice-Statements/ASTRO-39:s-guideline-on-SBRT-for-early-stage-NSCLC>
 - ii. ESTRO/ACROP: <https://www.ncbi.nlm.nih.gov/pubmed/28687397>
- c. Relevant Accessible Radiation Protocols
 - i. RTOG 0236. SBRT in medically inoperable early NSCLC: <https://www.rtog.org/clinicaltrials/protocoltable/studydetails.aspx?study=0236>
 - ii. RTOG 0618. SBRT in operable early NSCLC: <http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=4650>
 - iii. RTOG 0813. SBRT in medically inoperable central NSCLC (Supplementary>Protocol): <https://www.ncbi.nlm.nih.gov/pubmed/30943123>
 - iv. RTOG 0915. SBRT in medically inoperable peripheral NSCLC: <http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=4673>
 - v. CHISEL trial. SBRT vs standard fractionation in stage I NSCLC (Supplementary): <https://www.ncbi.nlm.nih.gov/pubmed/30770291>
 - vi. LUSTRE trial. SBRT vs conventional hypofractionation in inoperable early NSCLC (Treatment Interventions & Table 1): <https://pubmed.ncbi.nlm.nih.gov/27876603/>

- d. Quality of Life/Toxicity
 - i. ROSEL PRO SABR vs surgery: <https://www.ncbi.nlm.nih.gov/pubmed/26492839>
 - ii. RTOG 0813. SBRT in medically inoperable central NSCLC (Table 3): <https://www.ncbi.nlm.nih.gov/pubmed/30943123>
 - iii. RTOG 0236. SBRT in medically inoperable NSCLC (Table 4/5): <https://www.ncbi.nlm.nih.gov/pubmed/20233825>
 - iv. Rib fracture rates analysis: <https://www.ncbi.nlm.nih.gov/pubmed/19410314/>
 - v. Brachial plexopathy in apical tumors: <https://www.ncbi.nlm.nih.gov/pubmed/19454366/>
 - vi. Recommended normal lung constraints: <https://pubmed.ncbi.nlm.nih.gov/30496880/>

10. NSCLC (Locally Advanced)

- a. Contouring
 - i. RTOG Atlas: <https://www.rtog.org/corelab/contouringatlas/lungatlas.aspx>
 - ii. ESTRO/ACROP guidelines: <https://www.ncbi.nlm.nih.gov/pubmed/29605476>
 - iii. eContour (PORT): <https://econtour.org/cases/96>
 - iv. Atlas of Mediastinal LN stations: <https://pubmed.ncbi.nlm.nih.gov/16111586/>
- b. Society Guidelines
 - i. ASTRO: <https://www.astro.org/Patient-Care-and-Research/Clinical-Practice-Statements/ASTRO-39:s-guideline-on-definitive-and-adjuvant-RT>
- c. Relevant Accessible Radiation Protocols
 - i. Definitive Chemoradiation
 - 1. RTOG 0617. Dose escalation in locally advanced NSCLC: <http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=4649>
 - 2. RTOG 1308. Photon vs proton dose escalation in advanced NSCLC (Table 1): <https://www.ncbi.nlm.nih.gov/pubmed/27142674>
 - ii. Post-Operative
 - 1. Lung ART. PORT in resected pN2+ NSCLC: http://www.ifct.fr/images/stories/Protocoles/DocsPratiques/IFCT-0503-LungArt/Protocole_LungART_v8.pdf
- d. Quality of Life/Toxicity
 - i. RTOG 0617 QOL: <https://www.ncbi.nlm.nih.gov/pubmed/26606200>
 - ii. IMRT vs 3D in RTOG 0617: <https://www.ncbi.nlm.nih.gov/pubmed/28034064>
 - iii. Heart V50 predicts OS: <https://pubmed.ncbi.nlm.nih.gov/27743888/>
 - iv. PACIFIC Trial Toxicity (Table 3): <https://www.ncbi.nlm.nih.gov/pubmed/28885881>

11. SCLC

- a. Contouring: see protocols for guidance
- b. Society Guidelines
 - i. ASTRO: <https://pubmed.ncbi.nlm.nih.gov/32222430/>
 - ii. ASCO/ACCP: <https://www.ncbi.nlm.nih.gov/pubmed/26351333>
 - iii. ESMO: <https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Small-Cell-Lung-Cancer>
- c. Relevant Accessible Radiation Protocols
 - i. LS-SCLC
 - 1. CONVERT. QD vs BID RT in LS-SCLC (Supplementary Appendix 4): <https://www.ncbi.nlm.nih.gov/pubmed/26792218>
 - ii. ES-SCLC
 - 1. RTOG 0937. Consolidative RT in ES-SCLC: <https://www.rtog.org/clinicaltrials/protocoltable/studydetails.aspx?action=openFile&FileID=11137>
- d. Quality of Life/Toxicity
 - i. CONVERT. QD vs BID RT in LS-SCLC (Table 4 toxicity): <https://www.ncbi.nlm.nih.gov/pubmed/28642008>

- ii. CREST trial. Thoracic RT in ES-SCLC (Table 2): <https://www.ncbi.nlm.nih.gov/pubmed/25230595>
- iii. RTOG 0212 PCI QOL: <https://www.ncbi.nlm.nih.gov/pubmed/21139020>

12. Breast (Early)

- a. Contouring
 - i. RTOG: <https://www.rtog.org/corelab/contouringatlases/breastcanceratlas.aspx>
 - ii. ESTRO: <https://www.ncbi.nlm.nih.gov/pubmed/26791404>
 - iii. RADCOMP: <https://www.rtog.org/CoreLab/ContouringAtlases/RADCOMPBreastAtlas.aspx>
 - iv. eContour (early): <https://econtour.org/cases/73>
 - v. eContour (nodes): <https://econtour.org/cases/74>
 - vi. eContour (PBI): <http://econtour.org/cases/108>
 - vii. eContour (Ultrahypofractionation): <http://econtour.org/cases/117>
- b. Society Guidelines
 - i. ASTRO whole breast irradiation: <https://www.ncbi.nlm.nih.gov/pubmed/29545124>
 - ii. ASTRO APBI: <https://www.ncbi.nlm.nih.gov/pubmed/27866865>
 - iii. ASBS: <https://www.breastsurgeons.org/about/statements/>
 - iv. ASTRO/SSO stage I/II surgical margins: <https://www.ncbi.nlm.nih.gov/pubmed/24516019>
- c. Relevant Accessible Radiation Protocols
 - i. Whole breast
 - 1. RTOG 1005. WBI+SIB: <https://www.rtog.org/clinicaltrials/protocoltable/studydetails.aspx?action=openFile&FileID=9366>
 - 2. FAST Forward Ultrahypofractionation (appendix): <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262592/>
 - ii. Accelerated Partial Breast
 - 1. UK Import Low (Appendix): <https://www.ncbi.nlm.nih.gov/pubmed/28779963>
 - 2. RAPID trial (Appendix): <https://www.ncbi.nlm.nih.gov/pubmed/23835717>
 - 3. RTOG 0413/NSABP B-39: http://rpc.mdanderson.org/rpc/credentialing/files/B39_Protocol1.pdf
 - 4. RTOG 1014. Breast re-irradiation w/ APBI <https://www.rtog.org/clinicaltrials/protocoltable/studydetails.aspx?action=openFile&FileID=6358>
 - iii. Comprehensive Nodal
 - 1. MA.20 (supplementary): <https://www.ncbi.nlm.nih.gov/pubmed/26200977>
 - 2. EORTC 22922 (supplementary): <https://www.ncbi.nlm.nih.gov/pubmed/26200978>
- d. Quality of Life/Toxicity
 - i. Acute and short-term tox in standard vs hypo fractionated WBI: <https://www.ncbi.nlm.nih.gov/pubmed/26247543>
 - ii. 3yr outcomes standard vs hypofractionation WBI, all: <https://www.ncbi.nlm.nih.gov/pubmed/30379626>
 - iii. FAST Forward Ultrahypofractionation 5yr outcomes: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262592/>
 - iv. EORTC 22922 toxicity analysis: <https://www.ncbi.nlm.nih.gov/pubmed/20100142>
 - v. Intracavitary vs external beam APBI : <https://www.ncbi.nlm.nih.gov/pubmed/30125673>
 - vi. GEC-ESTRO interstitial APBI vs WBI QoL: <https://www.ncbi.nlm.nih.gov/pubmed/29695348>

13. Breast (Post Mastectomy)

- a. Contouring
 - i. RTOG: <https://www.rtog.org/corelab/contouringatlases/breastcanceratlas.aspx>
 - 1. Beriwal commentary: <https://www.ncbi.nlm.nih.gov/pubmed/26383675>

- ii. eContour (PMRT): <https://econtour.org/cases/75>
 - iii. eContour (Hypofractionated PMRT): <http://econtour.org/cases/110>
 - iv. ESTRO/ACROP implant based immediate reconstruction: <https://www.ncbi.nlm.nih.gov/pubmed/31108277>
- b. Society Guidelines
 - i. ASCO/ASTRO/SSO PMRT guideline update: <https://www.astro.org/Patient-Care-and-Research/Clinical-Practice-Statements/ASTRO-39;s-guideline-on-post-mastectomy-radiothera>
 - ii. ASBS: <https://www.breastsurgeons.org/about/statements/>
- c. Relevant Accessible Radiation Protocols
 - i. SUPREMO. PMRT in intermediate risk: <https://www.supremo-trial.com/SUPREMO%20protocol%20version27.pdf>
 - ii. NSABP B-51. With/without PMRT in ypN0 (Table 3 constraints): <https://www.ncbi.nlm.nih.gov/pubmed/26617210>
 - iii. RT CHARM. Hypofractionated PMRT: <https://www.allianceforclinicaltrialsinoncology.org/main/cmsfile?cmsPath=/Public/Annual%20Meeting/files/A221505-Poppe-May2019.pdf>
- d. Techniques/Historical Fields
 - i. DBCCG PMRT: <https://www.ncbi.nlm.nih.gov/pubmed/18465333>
 - ii. Comparison of seven PMRT techniques: <https://www.ncbi.nlm.nih.gov/pubmed/11955732>
 - iii. PMRT 2D techniques: <https://www.ncbi.nlm.nih.gov/pubmed/10378965>
- e. Quality of Life/Toxicity
 - i. SUPREMO QoL: <https://www.ncbi.nlm.nih.gov/pubmed/30337220>
 - ii. Lymphedema risk: <https://pubmed.ncbi.nlm.nih.gov/24411624/>

14. Gliomas (HGG & LGG)

- a. Contouring
 - i. GBM ESTRO-ACROP: <https://www.ncbi.nlm.nih.gov/pubmed/26777122>
 - ii. Brain OARs and Constraints: <https://www.ncbi.nlm.nih.gov/pubmed/25701297>
 - iii. EPTN Consensus Atlas for CNS OARs: <https://pubmed.ncbi.nlm.nih.gov/29548560/>
 - iv. NRG Consensus GBM Contouring Guidelines: <https://pubmed.ncbi.nlm.nih.gov/30888558/>
- b. Society Guidelines
 - i. ASTRO/ASCO GBM: <https://www.ncbi.nlm.nih.gov/pubmed/27893327>
 - ii. ESMO HGG: <https://www.esmo.org/Guidelines/Neuro-Oncology/High-Grade-Malignant-Glioma>
- c. Relevant Accessible Radiation Protocols (High Grade)
 - i. RTOG 0825. CRT with/without Avastin GBM (Supplementary): <https://www.ncbi.nlm.nih.gov/pubmed/24552317>
 - ii. RTOG 0525 (RTOG & EORTC protocols). CRT with/without ddTMZ GBM (Methods>Study Design and Treatment): <https://www.ncbi.nlm.nih.gov/pubmed/24101040>
 - iii. Short course 40Gy in 15fx (Supplementary): <https://www.ncbi.nlm.nih.gov/pubmed/28296618>
 - iv. IAEA Elderly GBM 25Gy in 5fx vs 40Gy in 15fx (Supplementary): <https://www.ncbi.nlm.nih.gov/pubmed/26392096>
 - v. RTOG 1205. Recurrent GBM: <https://www.rtog.org/clinicaltrials/protocoltable/studydetails.aspx?action=openFile&FileID=13508>
 - vi. CATNON. Anaplastic glioma non-codel 2x2 RT and TMZ: <http://www.eortc.be/services/doc/protocols/26053-22054-version4.0.pdf>

- vii. RTOG 9402. RT with/without PCV in anaplastic oligo (supplementary):
<https://www.ncbi.nlm.nih.gov/pubmed/23071247>
- viii. EORTC 26053. RT with/without PCV in anaplastic oligos (Targets in methods):
<https://www.ncbi.nlm.nih.gov/pubmed/16782911>
- d. Relevant Accessible Radiation Protocols (Low Grade)
 - i. RTOG 9802. LGG RT with/without PCV (supplementary):
<https://www.ncbi.nlm.nih.gov/pubmed/27050206>
 - ii. RTOG 0424: High risk LGG CRT w TZM (methods):
<https://www.ncbi.nlm.nih.gov/pubmed/25680596>
 - iii. EORTC 22033. LGG RT vs TMZ: <http://www.eortc.be/services/doc/protocols/22033-26033-version2.2.pdf>
- e. Quality of Life/Toxicity
 - i. Stupp trial QoL: <https://www.ncbi.nlm.nih.gov/pubmed/16321761>
 - ii. French Elderly GBM RT (Table 3): <https://www.ncbi.nlm.nih.gov/pubmed/17429084>
 - iii. TTF QOL: <https://www.ncbi.nlm.nih.gov/pubmed/29392280>
 - iv. RTOG 9402 QoL: <https://www.ncbi.nlm.nih.gov/pubmed/19783377>
 - v. EORTC 22033 QoL: <https://www.ncbi.nlm.nih.gov/pubmed/27686943>

15. Miscellaneous Brain/Spine

- a. Contouring
 - i. RTOG 0933 Atlas Hippocampal Sparing:
https://www.nrgoncology.org/Portals/0/Scientific%20Program/CIRO/Atlases/RTOG_Contouring_Guidelines-Hippocampus_version2.ppt
 - ii. International Sacral SBRT Contouring Guidelines:
<https://pubmed.ncbi.nlm.nih.gov/31874346/>
 - iii. Spine SBRT Contouring Guidelines: <https://pubmed.ncbi.nlm.nih.gov/27843035/>
 - iv. Post Op SRS brain mets: <https://www.ncbi.nlm.nih.gov/pubmed/29157748>
 - v. ISRC spine SRS volume guidelines: <https://www.ncbi.nlm.nih.gov/pubmed/22608954>
- b. Society Guidelines
 - i. EANO. Meningiomas: <https://www.ncbi.nlm.nih.gov/pubmed/27599143>
- c. Relevant Accessible Radiation Protocols
 - i. RTOG 0539. High risk meningiomas:
<https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=4644>
 - ii. NRG CC-001 HS-WBRT:
http://rpc.mdanderson.org/rpc/credentialing/files/CC001%20protocol_Preactivation%20revisions_RTQA%20edits%206-1-15.docx
 - iii. RTOG 0631. Spine SRS (Methods> Spine radiosurgery procedure):
<https://www.ncbi.nlm.nih.gov/pubmed/24890347>
- d. Quality of Life/Toxicity
 - i. Cognitive function after hippocampal sparing:
<https://pubmed.ncbi.nlm.nih.gov/32058845/>

16. Bladder

- a. Contouring
 - i. PORT: <https://www.ncbi.nlm.nih.gov/pubmed/27511849>
 - ii. NRG Atlas (postop):
[https://www.nrgoncology.org/Portals/0/Contouring%20guidelines%20for%20adjuvant%20RT%20for%20bladder%20Ca-%20NRG%20GU001%202016Aug21%20\[Read-Only\].pdf](https://www.nrgoncology.org/Portals/0/Contouring%20guidelines%20for%20adjuvant%20RT%20for%20bladder%20Ca-%20NRG%20GU001%202016Aug21%20[Read-Only].pdf)
 - iii. eContour: <http://econtour.org/cases/63>
 - iv. CTV in MIBC: <https://www.ncbi.nlm.nih.gov/pubmed/19394154>
 - v. RTOG normal tissue contouring guidelines:
<https://www.ncbi.nlm.nih.gov/pubmed/22483697>

- b. Society Guidelines
 - i. AUA/ASCO/ASTRO/SUO: <https://www.ncbi.nlm.nih.gov/pubmed/28456635>
- c. Relevant Accessible Radiation Protocols
 - i. BC 2001. RT with/without chemo: <https://www.birmingham.ac.uk/Documents/college-meds/trials/crcu/bc2001/Investigators/Trial-Protocol.pdf>
 - ii. RTOG 0712. CRT BID cis/5FU vs CRT QD gem: <https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=4659>
 - iii. HYBRID trial. Palliative IGRT weekly RT (supplementary): <https://www.ncbi.nlm.nih.gov/pubmed/28586948>
 - iv. NRG GU001. PORT IMRT in pT3/4: https://clinicaltrials.gov/ProvidedDocs/48/NCT02316548/Prot_SAP_000.pdf
- d. Quality of Life/Toxicity
 - i. BC2001 acute tox (Table 2): <https://www.ncbi.nlm.nih.gov/pubmed/22512481>
 - ii. RTOG pooled analysis late tox: <https://www.ncbi.nlm.nih.gov/pubmed/19636019>
 - iii. GETUG 97-015 QOL: <https://www.ncbi.nlm.nih.gov/pubmed/20385453>
 - iv. QOL in bladder preservation review: <https://www.ncbi.nlm.nih.gov/pubmed/26343030>
 - v. HYBRID trial: <https://www.ncbi.nlm.nih.gov/pubmed/28586948>

17. Rectum

- a. Contouring
 - i. eContour (Preop): <http://econtour.org/cases/11>
 - ii. eContour (Short course): <http://econtour.org/cases/95>
 - iii. International CTV consensus: <https://www.ncbi.nlm.nih.gov/pubmed/27528121>
 - iv. RTOG anorectal atlas: <https://www.rtog.org/LinkClick.aspx?fileticket=DqflROvKQ6w%3d&tabid=231>
- b. Society Guidelines
 - i. ASCRS: <https://www.fascrs.org/physicians/clinical-practice-guidelines>
 - ii. ESMO: <https://www.esmo.org/Guidelines/Gastrointestinal-Cancers/Rectal-Cancer>
 - iii. ASTRO: <https://www.ncbi.nlm.nih.gov/pubmed/26922700>
 - iv. ACR Appropriateness resectable: <https://www.ncbi.nlm.nih.gov/pubmed/23006527>
 - v. ACR Appropriateness local excision: <https://pubmed.ncbi.nlm.nih.gov/31445109/>
- c. Relevant Accessible Radiation Protocols
 - i. RTOG 0822. Preop CRT IMRT: <https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=4663>
 - ii. TROG 0104. Preop 5Gyx5 vs 50.4Gy box technique (supplementary): <https://www.ncbi.nlm.nih.gov/pubmed/23008301>
 - iii. German Rectal Trial. Preop vs postop CRT (Methods): <https://www.ncbi.nlm.nih.gov/pubmed/11370551>
 - iv. Stockholm III. Fractionation and time before surgery (Methods): <https://www.ncbi.nlm.nih.gov/pubmed/20155787>
- d. Quality of Life/Toxicity
 - i. RTOG 0822 IMRT tox (table 3): <https://www.ncbi.nlm.nih.gov/pubmed/26163334>
 - ii. German Rectal Trial. Preop vs postop tox (table 5): <https://www.ncbi.nlm.nih.gov/pubmed/15496622>
 - iii. TROG 0104. Preop short vs long tox (table 4): <https://www.ncbi.nlm.nih.gov/pubmed/23008301>
 - iv. Dutch TME trial with/without preop short QOL: <https://www.ncbi.nlm.nih.gov/pubmed/25060825>
 - v. MRC CR07. Preop vs postop QOL: <https://www.ncbi.nlm.nih.gov/pubmed/20585099>

18. Anal

- a. Contouring

- i. eContour: <https://econtour.org/cases/10>
 - ii. AGITG: <https://www.ncbi.nlm.nih.gov/pubmed/22401917>
 - iii. RTOG anorectal atlas: <https://www.rtog.org/LinkClick.aspx?fileticket=DqflROvKQ6w%3d&tabid=231>
 - iv. Technical Aspects of RT for anal cancer: <https://www.ncbi.nlm.nih.gov/pubmed/24982768>
- b. Society Guidelines
 - i. ASCRS: <https://www.fascrs.org/physicians/clinical-practice-guidelines>
 - ii. ESMO: <https://www.esmo.org/Guidelines/Gastrointestinal-Cancers/Anal-Cancer>
- c. Relevant Accessible Radiation Protocols
 - i. RTOG 0529. CRT IMRT: <https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0529>
 - ii. RTOG 9811. CRT 5FU/MMC vs 5FU/cisplatin: <https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=9811>
 - iii. ACCORD 03. CRT with/without induction or high dose RT (supplementary): <https://www.ncbi.nlm.nih.gov/pubmed/22529257>
- d. Quality of Life/Toxicity
 - i. RTOG 0529 IMRT tox (tables 4/5): <https://www.ncbi.nlm.nih.gov/pubmed/23154075>
 - ii. RTOG 9811 CRT MMC vs cis tox (table 3): <https://www.ncbi.nlm.nih.gov/pubmed/23150707>
 - iii. QOL in Norwegian national cohort: <https://www.ncbi.nlm.nih.gov/pubmed/23438358>
 - iv. QOL in IMRT cohort: <https://www.ncbi.nlm.nih.gov/pubmed/25194664>
 - v. QOL in Tomo cohort: <https://www.ncbi.nlm.nih.gov/pubmed/27406441>
 - vi. Patient reported QOL after IMRT: <https://pubmed.ncbi.nlm.nih.gov/32109852/>

19. Endometrial

- a. Contouring
 - i. eContour (pelvic RT): <https://econtour.org/cases/53>
 - ii. eContour (vaginal cuff brachy): <http://econtour.org/cases/57>
 - iii. Consensus post op IMRT volume guidelines: <https://www.ncbi.nlm.nih.gov/pubmed/18037584>
 - iv. RTOG GYN atlas: https://www.rtog.org/LinkClick.aspx?fileticket=Y_VFtGTy7-l%3d&tabid=230
 - v. RTOG Female Pelvis atlas: <https://www.nrgoncology.org/Portals/0/Scientific%20Program/CIRO/Atlases/Female%20RTOG%20Normal%20Pelvis%20Atlas.pdf>
- b. Society Guidelines
 - i. ASCO/ASTRO: <https://www.ncbi.nlm.nih.gov/pubmed/26150442>
 - ii. SGO: <https://www.sgo.org/practice-management/statements-and-recommendations/>
 - iii. FIGO: <https://www.ncbi.nlm.nih.gov/pubmed/30306580>
 - iv. ESMO: <https://www.esmo.org/Guidelines/Gynaecological-Cancers/Endometrial-Cancer>
 - v. ABS:
 - 1. HDR fractionation compendium: <https://www.ncbi.nlm.nih.gov/pubmed/30979631>
 - 2. Vaginal cuff consensus statement: <https://www.ncbi.nlm.nih.gov/pubmed/22265439>
 - 3. Non-operative consensus statement: <https://www.ncbi.nlm.nih.gov/pubmed/26186975>
- c. Relevant Accessible Radiation Protocols
 - i. RTOG 1203 (TIME-C). PORT 3DCRT vs IMRT (supplementary): <https://www.ncbi.nlm.nih.gov/pubmed/29989857>
 - ii. PORTEC-3. WPRT with/without concurrent chemo in high risk endometrial: <https://www.msbi.nl/promise/Projects/PORTEC3.aspx>

- iii. PORTEC-4. VCB (2 regimens) vs obs in high-intermediate risk: <https://www.msbi.nl/promise/LinkClick.aspx?fileticket=hxkNW1k6xl=>
- iv. PORTEC-4a. Molecular Profile Based Adjuvant Tx after surgery <https://www.msbi.nl/promise/LinkClick.aspx?fileticket=ze9k6rHS-bE%3d&tabid=125&portalid=0&mid=581>
- v. GOG 258. Chemotherapy with/without WPRT in advanced endometrial (supplementary): <https://www.ncbi.nlm.nih.gov/pubmed/31189035>
- d. Quality of Life/Toxicity
 - i. RTOG 1203 QOL 3D vs IMRT: <https://www.ncbi.nlm.nih.gov/pubmed/29989857>
 - ii. PORTEC 1 QOL with/without WPRT: <https://www.ncbi.nlm.nih.gov/pubmed/21444867>
 - iii. PORTEC 2 VCB vs WPRT tox (Figure 3): <https://www.ncbi.nlm.nih.gov/pubmed/20206777>
 - iv. PORTEC 3 QOL WPRT with/without concurrent chemo: <https://www.ncbi.nlm.nih.gov/pubmed/27397040>

20. Cervical

- a. Contouring
 - i. eContour (intact): <https://econtour.org/cases/38>, <http://econtour.org/cases/111>
 - ii. eContour (postop): <https://econtour.org/cases/55>
 - iii. Consensus intact IMRT volume guidelines: <https://www.ncbi.nlm.nih.gov/pubmed/20472347>
 - iv. Pictorial atlas for intact: <https://pubmed.ncbi.nlm.nih.gov/27032573/>
 - v. Consensus post op IMRT volume guidelines: <https://www.ncbi.nlm.nih.gov/pubmed/18037584>
 - vi. RTOG GYN atlas: https://www.rtog.org/LinkClick.aspx?fileticket=Y_VFtGTy7-l%3d&tabid=230
 - vii. RTOG Female Pelvis atlas: <https://www.nrgoncology.org/Portals/0/Scientific%20Program/CIRO/Atlases/Female%20RTOG%20Normal%20Pelvis%20Atlas.pdf>
- b. Society Guidelines
 - i. ASTRO: <https://pubmed.ncbi.nlm.nih.gov/32473857/>
 - ii. ASCO: <https://www.ncbi.nlm.nih.gov/pubmed/28717717>
 - iii. SGO: <https://www.sgo.org/practice-management/statements-and-recommendations/>
 - iv. FIGO: <https://www.ncbi.nlm.nih.gov/pubmed/30306584>
 - v. ESMO: <https://www.esmo.org/Guidelines/Gynaecological-Cancers/Cervical-Cancer>
 - vi. ESTRO/ESGO: <https://pubmed.ncbi.nlm.nih.gov/29728273/>
 - vii. ABS:
 - 1. General principles: <https://www.ncbi.nlm.nih.gov/pubmed/22265436>
 - 2. HDR fractionation compendium: <https://www.ncbi.nlm.nih.gov/pubmed/30979631>
 - 3. HDR guidelines: <https://www.ncbi.nlm.nih.gov/pubmed/22265437>
 - 4. LDR & PDR guidelines: <https://www.ncbi.nlm.nih.gov/pubmed/22265438>
- c. Relevant Accessible Radiation Protocols
 - i. RTOG 1203 (TIME-C). PORT 3DCRT vs IMRT (supplementary): <https://pubmed.ncbi.nlm.nih.gov/29989857/>
 - ii. OUTBACK trial. CRT with/without adj chemo (whole pelvis and extended field): <https://www.rtog.org/clinicaltrials/protocoltable/studydetails.aspx?action=openFile&FileID=10105>
 - iii. RTOG 0417. CRT w avastin (whole pelvis field): <https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=4625>
 - iv. RTOG 0418 Postop IMRT: <https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=13703>

- v. EMRBACE II Benchmarking with Advanced EBRT and Brachy Techniques: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862686/>
- d. Quality of Life/Toxicity
 - i. RTOG 1203 QOL PORT 3D vs IMRT: <https://www.ncbi.nlm.nih.gov/pubmed/29989857>
 - ii. RTOG 9001 CRT vs EFRT tox (table 6): <https://www.ncbi.nlm.nih.gov/pubmed/14990643>
 - iii. Toxicity after image guided Brachy (Table 1): [https://www.brachyjournal.com/article/S1538-4721\(16\)30054-X/fulltext](https://www.brachyjournal.com/article/S1538-4721(16)30054-X/fulltext)

21. Vaginal/Vulvar

- a. Contouring
 - i. eContour (vaginal): <https://econtour.org/cases/51>
 - ii. Consensus vulvar contouring: <https://www.ncbi.nlm.nih.gov/pubmed/27130794>
 - iii. RTOG Female Pelvis atlas: <https://www.nrgoncology.org/Portals/0/Scientific%20Program/CIRO/Atlases/Female%20RTOG%20Normal%20Pelvis%20Atlas.pdf>
- b. Society Guidelines
 - i. FIGO report vaginal cancer 2018: <https://www.ncbi.nlm.nih.gov/pubmed/30306589>
 - ii. FIGO report vulvar cancer 2018: <https://www.ncbi.nlm.nih.gov/pubmed/30306583>
 - iii. ABS vaginal consensus statement: <https://www.ncbi.nlm.nih.gov/pubmed/22265440>
- c. Relevant Accessible Radiation Protocols
 - i. GOG 205. CRT with weekly cisplatin for vulvar (methods): <https://www.ncbi.nlm.nih.gov/pubmed/22079361>
 - ii. WashU vulvar IMRT technique (methods): <https://www.ncbi.nlm.nih.gov/pubmed/28740926>
 - iii. Pittsburg vulvar IMT technique (methods): <https://www.ncbi.nlm.nih.gov/pubmed/16442238>

22. Head & Neck

- a. Contouring
 - i. eContour (many cases): <https://econtour.org/cases>
 - ii. DAHANCA/EORTC/RTOG/etc cranial nerve & nodal atlases: <https://www.rtog.org/CoreLab/ContouringAtlases/HNAtlases.aspx>
 - iii. GORTEC Trigeminal Nerve Contouring: <https://pubmed.ncbi.nlm.nih.gov/30206021/>
 - iv. European definitive RT lymph node targets 2019: <https://www.ncbi.nlm.nih.gov/pubmed/31005201>
 - v. Brachial plexus contouring: <https://www.ncbi.nlm.nih.gov/pubmed/18448267>
 - vi. Nasopharynx CTVs: <https://www.ncbi.nlm.nih.gov/pubmed/29153464>
 - vii. Nasopharynx OARs: <https://www.ncbi.nlm.nih.gov/pubmed/24721546>
 - viii. Nasopharynx dose prioritizations: <https://www.ncbi.nlm.nih.gov/pubmed/31276776>
 - ix. DAHANCA/EORTC/RTOG/etc consensus guidelines definitive RT lymph node targets 2013: <https://www.ncbi.nlm.nih.gov/pubmed/24183870>
 - x. DAHANCA/EORTC/NRG/etc CTV-P definitive RT consensus guidelines 2018: <https://www.ncbi.nlm.nih.gov/pubmed/29180076>
 - xi. DAHANCA/EORTC/GORTEC/etc OAR consensus: <https://www.ncbi.nlm.nih.gov/pubmed/26277855>
 - xii. H&N post op CTV targets: <https://www.ncbi.nlm.nih.gov/pubmed/30409314>
 - xiii. IMRT H&N targets selection and delineation: <https://www.ncbi.nlm.nih.gov/pubmed/12118389>
 - xiv. Perineural tumor spread: <https://pubmed.ncbi.nlm.nih.gov/30562546/>
- b. Society Guidelines
 - i. ASTRO OPC Guideline: <https://www.astro.org/Patient-Care-and-Research/Clinical-Practice-Statements/ASTRO-39;s-guideline-on-oropharyngeal-squamous-cel>

- ii. ASCO H&N Guidelines: <https://www.asco.org/research-guidelines/quality-guidelines/guidelines/head-and-neck-cancer>
- iii. ASCO Unknown Primary Guideline: <https://pubmed.ncbi.nlm.nih.gov/32324430/>
- iv. ESMO H&N guidelines: <https://www.esmo.org/Guidelines/Head-and-Neck-Cancers>
- c. Relevant Accessible Radiation Protocols
 - 1. RTOG 1008. RT vs CRT in salivary gland tumors: <http://rpc.mdanderson.org/rpc/credentialing/files/1008.pdf>
 - 2. RTOG 1016. CRT cis vs cetux in HPV+ OPC: <https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=8629>
 - 3. RTOG 9512. Hyper vs conventional fractionation T2 larynx: <https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=6109>
 - 4. Early Glottic Field Borders (Figure 1): <https://www.ncbi.nlm.nih.gov/pubmed/3143690>
 - 5. CRT NPX with/without induction Gem/Cis (supplementary): <https://www.ncbi.nlm.nih.gov/pubmed/31150573>
 - 6. ORATOR: TORS vs Definitive (chemo)RT for HPV+ oropharynx (supplementary): <https://pubmed.ncbi.nlm.nih.gov/31416685/>
- d. Quality of Life/Toxicity
 - i. 3DCRT vs IMRT in head & neck: <https://www.ncbi.nlm.nih.gov/pubmed/26561342>
 - ii. Long term QOL after IMRT: <https://pubmed.ncbi.nlm.nih.gov/32051896/>
 - iii. CRT NPX with/without induction Gem/Cis tox (Table 3): <https://www.ncbi.nlm.nih.gov/pubmed/31150573>
 - iv. RTOG 1016. CRT cis vs cetux in HPV+ OPC tox and QOL (Table 2 & supplementary): <https://www.ncbi.nlm.nih.gov/pubmed/30449625>
 - v. RTOG 9111. RT vs chemo+RT vs CRT in advanced larynx:
 - 1. Toxicity (table 2): <https://www.ncbi.nlm.nih.gov/pubmed/14645636>
 - 2. Swallowing (methods>speech & swallowing): <https://www.ncbi.nlm.nih.gov/pubmed/15128893>
 - vi. RTOG 9501. Postop RT vs CRT tox (Table 2): <https://www.ncbi.nlm.nih.gov/pubmed/15128893>
 - vii. ORATOR: TORS vs Definitive (chemo)RT for HPV+ oropharynx: <https://pubmed.ncbi.nlm.nih.gov/31416685/>

23. Esophageal and Gastric

- a. Contouring
 - i. eContour (preop): <http://econtour.org/cases/60>
 - ii. eContour (upper abdominal OARs): <http://econtour.org/cases/112>
 - iii. RTOG upper GI OAR atlas: https://www.rtog.org/LinkClick.aspx?fileticket=dgwtzf553_q%3d&tabid=387
 - iv. MRI Based OAR Contouring: <https://pubmed.ncbi.nlm.nih.gov/31953061/>
 - v. ARRO esophageal contour: https://www.astro.org/uploadedFiles/MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/EsophagealContour.pdf
 - vi. Consensus esophageal and GEJ contouring: <https://www.ncbi.nlm.nih.gov/pubmed/26104943>
 - vii. Gastric lymph node contouring atlas: <https://www.ncbi.nlm.nih.gov/pubmed/24674268>
 - viii. EORTC opinion RT volumes and constraints: <https://www.ncbi.nlm.nih.gov/pubmed/19375186>
- b. Society Guidelines
 - i. EORTC GEJ and gastric guidelines: <https://www.ncbi.nlm.nih.gov/pubmed/19375186>

- ii. ESMO gastric guidelines: <https://www.esmo.org/Guidelines/Gastrointestinal-Cancers/Gastric-Cancer>
- iii. ESMO esophageal guidelines: <https://www.esmo.org/Guidelines/Gastrointestinal-Cancers/Oesophageal-Cancer>
- c. Relevant Accessible Radiation Protocols
 - i. CROSS trial. Esophageal preop RT vs CRT (supplementary): <https://www.ncbi.nlm.nih.gov/pubmed/22646630>
 - ii. RTOG 0436. Non-operative esophageal CRT with/without Cetuximab: <https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=4629>
 - iii. RTOG 1010. Esophageal preop CRT with/without Traztuzamab: <https://www.rtog.org/LinkClick.aspx?fileticket=52jdx-MJBUQ%3D&tabid=290>
 - iv. CRITICS. Periop chemo vs CRT in gastric: <http://www.cirro.dk/assets/files/Protokoller/CIRRO-IP050109-CRITICS.pdf>
 - v. RTOG 9904. Preop CRT in gastric: <https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=7555>
 - vi. RTOG 0114. Adj cis/taxol CRT in gastric: <https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=7533>
 - vii. Review of 2D adjuvant gastric RT: <https://www.ncbi.nlm.nih.gov/pubmed/11872272>
- d. Quality of Life/Toxicity
 - i. CROSS trial. Esophageal preop RT vs CRT
 - 1. Tox (table 2): <https://www.ncbi.nlm.nih.gov/pubmed/22646630>
 - 2. QOL: <https://www.ncbi.nlm.nih.gov/pubmed/29161204>
 - ii. CRITICS. Preop chemo vs CRT in gastric
 - 1. Tox (table 4): <https://pubmed.ncbi.nlm.nih.gov/29650363/>
 - 2. QOL: https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4060
 - iii. Adjuvant CRT QOL: https://ascopubs.org/doi/abs/10.1200/jco.2016.34.4_suppl.164
 - iv. INT 0116. Surgery with/without adj CRT in gastric tox (table 3): <https://www.ncbi.nlm.nih.gov/pubmed/11547741>

24. Pancreas

- a. Contouring
 - i. eContour (postop): <http://econtour.org/cases/4>
 - ii. eContour (upper abdominal OARs): <http://econtour.org/cases/112>
 - iii. RTOG postop ATLAS: <https://www.rtog.org/LinkClick.aspx?fileticket=CLd1-1PWZek%3d&tabid=237>
 - iv. RTOG postop CTV consensus: <https://www.ncbi.nlm.nih.gov/pubmed/22483737>
 - v. Preop CTVn volumes: <https://www.ncbi.nlm.nih.gov/pubmed/22691275>
 - vi. ARRO preop pancreas contour: https://www.astro.org/uploadedFiles/MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/ARROContourBRPancreas.pdf
 - vii. MRI based GTV Contouring: <https://pubmed.ncbi.nlm.nih.gov/29426692/>
 - viii. MRI Based OAR Contouring: <https://pubmed.ncbi.nlm.nih.gov/31953061/>
- b. Society Guidelines
 - i. ASTRO: <https://pubmed.ncbi.nlm.nih.gov/31474330/>
 - ii. ASCO locally advanced pancreas guidelines: <https://www.ncbi.nlm.nih.gov/pubmed/27247216>
 - iii. ASCO curable pancreas guidelines: <https://pubmed.ncbi.nlm.nih.gov/28398845/>
 - iv. ESMO: <https://www.esmo.org/Guidelines/Gastrointestinal-Cancers/Cancer-of-the-Pancreas>
 - v. ISGPS borderline resectable: <https://www.ncbi.nlm.nih.gov/pubmed/24856119>

- vi. TROG pancreatic SBRT: <https://pubmed.ncbi.nlm.nih.gov/31761541/>
- c. Relevant Accessible Radiation Protocols
 - i. LAP07. Chemo vs CRT in adv pancreas (supplementary): <https://www.ncbi.nlm.nih.gov/pubmed/27139057>
 - ii. RTOG 1201. 50.4Gy vs 63Gy CRT in adv pancreas: <https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=10172>
 - iii. RTOG 9704. Adj CRT with pre/post 5FU vs Gem: <https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=7546>
 - iv. RTOG 0848. Adj chemo with/without CRT: <http://rpc.mdanderson.org/rpc/credentialing/files/0848.pdf>
 - v. Hopkins SBRT 33Gy/5fx pancreas (methods): <https://www.ncbi.nlm.nih.gov/pubmed/25538019>
 - vi. MGH SBRT 24-36Gy/3fx pancreas (methods): <https://www.ncbi.nlm.nih.gov/pubmed/21658854>
 - vii. Moffitt SBRT pancreas (methods): <https://www.ncbi.nlm.nih.gov/pubmed/23562768>
 - viii. Various hypo-fractionation constraints (table 4): <https://www.ncbi.nlm.nih.gov/pubmed/27233119>
- d. Quality of Life/Toxicity
 - i. LAP07. Chemo vs CRT in adv pancreas tox (table 2): <https://www.ncbi.nlm.nih.gov/pubmed/27139057>
 - ii. ESPAC-1. Postop chemo vs CRT QOL (results): <https://www.ncbi.nlm.nih.gov/pubmed/11716884>
 - iii. Various hypo-fractionation toxicities (table 2): <https://www.ncbi.nlm.nih.gov/pubmed/27233119>

25. Liver

- a. Contouring
 - i. eContour: <https://econtour.org/cases/76>
 - ii. eContour (upper abdominal OARs): <http://econtour.org/cases/112>
 - iii. RTOG upper abdominal OAR: https://www.rtog.org/LinkClick.aspx?fileticket=dgwtzf553_g%3d&tabid=387
 - iv. RTOG HCC target definition consensus: <https://www.ncbi.nlm.nih.gov/pubmed/24969794>
 - v. CTV Atlas for Biliary Cancer: <https://pubmed.ncbi.nlm.nih.gov/30675238/>
 - vi. MRI Based OAR Contouring: <https://pubmed.ncbi.nlm.nih.gov/31953061/>
- b. Society Guidelines
 - i. AASLD: [https://www.aasld.org/sites/default/files/2019-06/AASLD 2018 HCC Guidance on Diagnosis%2C Staging and Management hep 29913%20%281%29.pdf](https://www.aasld.org/sites/default/files/2019-06/AASLD%202018%20HCC%20Guidance%20on%20Diagnosis%20Staging%20and%20Management%20hep%202018%20281%29.pdf)
 - ii. ACR/LI-RADS: <https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS>
 - iii. APPLE: <https://www.ncbi.nlm.nih.gov/pubmed/27493892>
 - iv. EASL-EORTC: <https://easl.eu/publication/easl-clinical-practice-guidelines-management-of-hepatocellular-carcinoma/>
 - v. ESMO: <https://www.esmo.org/Guidelines/Gastrointestinal-Cancers/Hepatocellular-Carcinoma>
- c. Relevant Accessible Radiation Protocols
 - i. RTOG 1112. Sorafenib with/without SBRT HCC: [https://www.rtog.org/Portals/0/RTOG Broadcasts/Attachments/1112 master w update 5.7.13.pdf](https://www.rtog.org/Portals/0/RTOG%20Broadcasts/Attachments/1112%20master%20w%20update%205.7.13.pdf)
 - ii. Princess Margaret Phase I/II SBRT in locally advanced HCC (Methods>Treatment & Appendix Tables): <https://www.ncbi.nlm.nih.gov/pubmed/23547075>

- iii. RTOG 0438. Hypofractionation in liver metastasis:
<https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=7411>
- iv. Phase I/II SBRT in liver metastases (Methods>Treatment):
<https://www.ncbi.nlm.nih.gov/pubmed/19255321>
- v. Phase II SBRT in inoperable liver metastases (Methods>Radiotherapy):
<https://www.ncbi.nlm.nih.gov/pubmed/25245052>
- d. Quality of Life/Toxicity
 - i. Princess Margaret phase I/II SBRT in locally advanced HCC (Table 2):
<https://www.ncbi.nlm.nih.gov/pubmed/23547075>
 - ii. Phase II SBRT in inoperable liver metastases (Results>Toxicity):
<https://www.ncbi.nlm.nih.gov/pubmed/25245052>
 - iii. QOL after liver SBRT: <https://pubmed.ncbi.nlm.nih.gov/26279020/>

26. Sarcoma

- a. Contouring
 - i. eContour (lower extremity preop): <http://econtour.org/cases/115>
 - ii. RTOG extremity soft tissue sarcoma atlas:
<https://www.rtog.org/LinkClick.aspx?fileticket=AThtvc6dabE%3d&tabid=356>
 - iii. Expert review and volume recommendations for extremity soft tissue sarcomas:
<https://www.ncbi.nlm.nih.gov/pubmed/22520481>
 - iv. International consensus for PreOp radiotherapy in retroperitoneal sarcoma:
<https://www.ncbi.nlm.nih.gov/pubmed/26068493>
 - v. NRG retroperitoneal sarcoma target volume and OAR agreement:
<https://www.ncbi.nlm.nih.gov/pubmed/26194680>
 - vi. RTOG extremity soft tissue sarcoma target volume agreement:
<https://www.ncbi.nlm.nih.gov/pubmed/23474110>
- b. Society Guidelines
 - i. ESMO: <https://www.esmo.org/Guidelines/Sarcoma-and-GIST>
 - ii. TARPSWG primary/recurrent RP sarcoma: <https://tarpswg.org/papers-from-tarpswg/>
 - iii. ABS: <https://pubmed.ncbi.nlm.nih.gov/28342738/>
- c. Relevant Accessible Radiation Protocols
 - i. RTOG 9514. Neoadj chemo, RT in STS of extremities, body wall:
<https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=10606>
 - ii. <https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=9379>
 - iii. RTOG 0630. IGRT in extremity STS:
 - iv. <https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=7540>
 - v. RTOG 0124. Multimodality treatment in primary/recurrent RP sarcoma:
<https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?action=openFile&FileID=7540>
 - vi. O'Sullivan. Preop vs PostOp extremity STS (Methods>Procedures):
<https://www.ncbi.nlm.nih.gov/pubmed/12103287>
- d. Quality of Life/Toxicity
 - i. O'Sullivan. Preop vs PostOp extremity STS tox (Tables 2/3):
<https://www.ncbi.nlm.nih.gov/pubmed/12103287>
 - ii. RTOG 0630. IGRT for extremity STS tox (Table 3):
<https://www.ncbi.nlm.nih.gov/pubmed/25667281>
 - iii. IMRT+IGRT extremity STS tox (Results>Secondary Endpoints):
<https://www.ncbi.nlm.nih.gov/pubmed/23423841>
 - iv. Dose-escalated IMRT and IORT RP STS tox (Tables 4/5):
<https://www.ncbi.nlm.nih.gov/pubmed/25163595>
 - v. QoL with PreOp RT in RP STS: <https://www.ncbi.nlm.nih.gov/pubmed/29234568>